FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029303085> ?p ?o ?g. }

• W2029303085 endingPage "1349" @default.
• W2029303085 startingPage "1334" @default.
• W2029303085 abstract "Denosumab has been approved in the United States for the prevention of skeletal-related events (SREs) in metastatic breast cancer. In a Phase III trial in patients with bone-metastatic breast cancer (N = 2033), denosumab was associated with a significantly delayed time to first SRE (by 18%; P < 0.001 noninferiority; P = 0.01 superiority) and time to first and subsequent SREs (by 23%; P = 0.001). Overall survival (HR = 0.95; 95% CI, 0.81-1.11; P = 0.49) and disease progression (HR = 1.00; 95% CI, 0.89-1.11; P = 0.93) did not differ significantly between groups. Denosumab was associated with a nonsignificant reduction in serious adverse events (44.4% vs 46.5%).Given the current ambiguity regarding the cost-effectiveness of these agents in light of these trial outcomes, the present analysis assessed, from a US payer perspective, the cost-effectiveness of denosumab versus zoledronic acid in patients with bone metastases secondary to breast cancer.A literature-based Markov model was developed to estimate the survival, quality-adjusted life-years (QALYs) gained, number and costs of SREs, and drug and administration costs in patients receiving denosumab or zoledronic acid over 27 and 60 months. Clinical inputs reproduced the trial outcomes. SRE-related costs and utilities were literature based. Costs and QALYs were discounted 3% annually.In the 27-month base-case analysis, denosumab was associated with fewer SREs (-0.298), more QALYs (+0.0102), and lower SRE-related costs (-$2016), but higher drug-related (+$9123) and total costs (+$7107) versus zoledronic acid. The cost per QALY gained (ie, incremental cost-effectiveness ratio [ICER]) was $697,499. In sensitivity analyses, the ICER ranged from $192,472 to $1,340,901/QALY, depending on assumptions regarding treatment benefits, drug costs, and analytical horizon. In the probabilistic sensitivity analysis, denosumab was cost-effective in 2 of 5000 modeled replicates (0.04%).Despite the limitations of restricted availability of clinical data and uncertainty regarding the price of generic zoledronic acid, the findings from the present analysis suggest that the use of denosumab is associated with a high ICER compared with zoledronic acid. This finding may raise important questions regarding the economic value of denosumab in bone-metastatic breast cancer." @default.
• W2029303085 created "2016-06-24" @default.
• W2029303085 creator A5055552324 @default.
• W2029303085 creator A5065512022 @default.
• W2029303085 creator A5070363076 @default.
• W2029303085 creator A5087184017 @default.
• W2029303085 date "2012-06-01" @default.
• W2029303085 modified "2023-09-23" @default.
• W2029303085 title "Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer" @default.
• W2029303085 cites W1651984822 @default.
• W2029303085 cites W1768011742 @default.
• W2029303085 cites W1842425533 @default.
• W2029303085 cites W1954585625 @default.
• W2029303085 cites W1966063111 @default.
• W2029303085 cites W1968549584 @default.
• W2029303085 cites W1969967745 @default.
• W2029303085 cites W1978331689 @default.
• W2029303085 cites W1978986376 @default.
• W2029303085 cites W1981367254 @default.
• W2029303085 cites W1984665134 @default.
• W2029303085 cites W1991890714 @default.
• W2029303085 cites W1994549732 @default.
• W2029303085 cites W1995615104 @default.
• W2029303085 cites W2006495870 @default.
• W2029303085 cites W2010030230 @default.
• W2029303085 cites W2011000634 @default.
• W2029303085 cites W2023962570 @default.
• W2029303085 cites W2037542472 @default.
• W2029303085 cites W2037864652 @default.
• W2029303085 cites W2044929258 @default.
• W2029303085 cites W2052592826 @default.
• W2029303085 cites W2054913380 @default.
• W2029303085 cites W2060301719 @default.
• W2029303085 cites W2061839701 @default.
• W2029303085 cites W2064936613 @default.
• W2029303085 cites W2065672662 @default.
• W2029303085 cites W2066327505 @default.
• W2029303085 cites W2079742505 @default.
• W2029303085 cites W2087653913 @default.
• W2029303085 cites W2088982930 @default.
• W2029303085 cites W2091388541 @default.
• W2029303085 cites W2094905849 @default.
• W2029303085 cites W2103164850 @default.
• W2029303085 cites W2108732235 @default.
• W2029303085 cites W2109361037 @default.
• W2029303085 cites W2123524368 @default.
• W2029303085 cites W2135630936 @default.
• W2029303085 cites W2137634233 @default.
• W2029303085 cites W2147876556 @default.
• W2029303085 cites W2148199952 @default.
• W2029303085 cites W2150126991 @default.
• W2029303085 cites W2159492992 @default.
• W2029303085 cites W2161962336 @default.
• W2029303085 cites W2165011173 @default.
• W2029303085 cites W2166769897 @default.
• W2029303085 cites W2167077733 @default.
• W2029303085 cites W2167795229 @default.
• W2029303085 cites W2328415352 @default.
• W2029303085 cites W2047204513 @default.
• W2029303085 doi "https://doi.org/10.1016/j.clinthera.2012.04.008" @default.
• W2029303085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22578308" @default.
• W2029303085 hasPublicationYear "2012" @default.
• W2029303085 type Work @default.
• W2029303085 sameAs 2029303085 @default.
• W2029303085 citedByCount "25" @default.
• W2029303085 countsByYear W20293030852012 @default.
• W2029303085 countsByYear W20293030852013 @default.
• W2029303085 countsByYear W20293030852014 @default.
• W2029303085 countsByYear W20293030852015 @default.
• W2029303085 countsByYear W20293030852016 @default.
• W2029303085 countsByYear W20293030852017 @default.
• W2029303085 countsByYear W20293030852018 @default.
• W2029303085 countsByYear W20293030852019 @default.
• W2029303085 countsByYear W20293030852021 @default.
• W2029303085 crossrefType "journal-article" @default.
• W2029303085 hasAuthorship W2029303085A5055552324 @default.
• W2029303085 hasAuthorship W2029303085A5065512022 @default.
• W2029303085 hasAuthorship W2029303085A5070363076 @default.
• W2029303085 hasAuthorship W2029303085A5087184017 @default.
• W2029303085 hasConcept C121608353 @default.
• W2029303085 hasConcept C126322002 @default.
• W2029303085 hasConcept C143998085 @default.
• W2029303085 hasConcept C2775930923 @default.
• W2029303085 hasConcept C2776286101 @default.
• W2029303085 hasConcept C2776326535 @default.
• W2029303085 hasConcept C2776541429 @default.
• W2029303085 hasConcept C530470458 @default.
• W2029303085 hasConcept C535046627 @default.
• W2029303085 hasConcept C71924100 @default.
• W2029303085 hasConceptScore W2029303085C121608353 @default.
• W2029303085 hasConceptScore W2029303085C126322002 @default.
• W2029303085 hasConceptScore W2029303085C143998085 @default.
• W2029303085 hasConceptScore W2029303085C2775930923 @default.
• W2029303085 hasConceptScore W2029303085C2776286101 @default.
• W2029303085 hasConceptScore W2029303085C2776326535 @default.
• W2029303085 hasConceptScore W2029303085C2776541429 @default.
• W2029303085 hasConceptScore W2029303085C530470458 @default.
• W2029303085 hasConceptScore W2029303085C535046627 @default.

• next